Evaluation of the Activity of Leea Indica Merrill in Inflammatory Bowel Disease using Experimental Models
DOI:
https://doi.org/10.37285/ijpsn.2018.11.4.9Abstract
Leea indica is traditionally well-known for its versatile uses. The present study was carried out to evaluate the protective effect of methanolic extract of Leea Indica on DNBS (2, 4 dinitrobenzene sulfonic acid) induced inflammatory bowel disease in rats. Adult Wistar rats of either sex weighing 150-200 g were selected. Thirty animals were randomly divided into 5 groups each consisting of 6 animals. The period of experiment was of 12 days. Animals of Group I, Group-III, Group-IV & Group-V were given water, methanolic extract of Leea indica (200mg/kg & 400mg/kg) and sulfasalazine (360 mg/kg body weight) respectively once a day orally for 1st to 7th days. On 8th day of the study, DNBS solution (30 mg dissolved in 0.25 ml of 50% ethanol) was administered intrarectally to induce IBD in animals of Group-II to V, on same day & no treatment was given. Then from 9th to 11th day, they were again given treatment. On 12th day, blood was collected from all animals and sacrificed and dissected to isolate colon. Finally, macroscopic, microscopic and biochemical studies were carried out. At all the two doses, the methanolic extract of Leea Indica showed significant anti-inflammatory activity in experimental models. Results obtained in this study substantiate the anti-inflammatory effect of methanolic extract of Leea Indica roots.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Keywords:
Leea indica, Inflammatory bowel disease, DNBS, Sufasalazine
Downloads
Published
2018-07-31
How to Cite
1.
Shah SK, Patel KM, Rathod NP. Evaluation of the Activity of Leea Indica Merrill in Inflammatory Bowel Disease using Experimental Models. Scopus Indexed [Internet]. 2018 Jul. 31 [cited 2024 May 5];11(4):4219-25. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/385
Issue
Section
Research Articles
References
AB Joshi, PU Tari and M Bhobhe (2013). Phytochemical investigation of the roots of Leea indica Merrill. Indian Journal of Research in Pharmaceutical and Biomedical Science 4: 919-923.
Abreu M.T (2002). The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr. Gastroenterol 4: 481-489.
Adeleye GS, Nwozor CM and Okafor CB (2013). Effects of Dietary Advanced Lipid Oxidation End-products on Colitis Healing in Albino Rats. Journal of Environmental Issues and Agriculture in Developing Countries 5: 56-59.
Bickson SJ (1998). Treatment of chronic disease at the turn of the century. N Engl J Med 339: 401-2.
Button LA, Roberts SE, Goldacre MJ, Akbari A, Rodgers SE and Williams JG (2010). Hospitalized prevalence and 5-year mortality for IBD: Record linkage study. World. J Gastroenterol 16: 431-438.
Calkins BM and Mendeloff AI (1995). The epidemiology of idiopathic inflammatory bowel disease, 4th ed. Williams and wilkins, Baltimore.
Ellman GL (1959). Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 82: 70-76.
Frank I Tovey, Doga Capanoglu, G John Langley, Julie M Herniman, Serhat Bor and Michael Hobsely (2011). Dietary phytosterols protective against peptic ulceration. Gastroenterology Research 4(4):149-156.
Geetha T and Varalakshmi P (2001). Anti-inflammatory activity of lupeol in rats. Ethnopharmacol 76(1): 77-80.
Giriş M, Depboylu B, Doğru-Abbasoğlu S, Erbil Y, Olgaç V and Aliş H (2008). Effect of taurine on oxidative stress and apoptosis-related protein expression in trinitrobenzene sulphonic acid-induced colitis. Clin Exp Immunol 152: 102-110.
Gupta A, Bhatt MLB and Misra MK (2009). Lipid peroxidation and antioxidant status in head and neck squamous cell carcinoma patients. Oxidative Medicine and Cellular Longevity 2: 68-72.
Hagar HH, Medany AE, Eta EE and Arafa M (2007). Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid induced colitis in rats. European Journal of Pharmacology 554(1): 69-77.
Hana Strul MD and Nadir Arber MD (2000). Inflammatory bowel disease, ulcerative colitis, Crohn’s disease, pathophysiology, new therapies. IMAJ 2: 607-609.
Hofer N (2003). OraSl budesonide in management of Crohn's disease. Ann Pharmacother 37: 1457-1464.
Jagtap AG, Shrike SS and Phadke AS (2004). Effect of polyherbal formulation on experimental models of inflammatory bowel diseases. Journal of Ethnopharmacology 90: 195-204.
Kirtikar KR and Basu BD (2005). Indian Medicinal Plants, 2nd ed. Uttranchal (India).
Ko JKS, Lam FYL and Cheung APL (2005). Amelioration of experimental colitis by Astragalus membranaceus through anti-oxidation and inhibition of adhesion molecule synthesis. World J. Gastroenterol 11: 5787-5794.
Kokate CK, Purohit A and Gokhale S (1990). The Book of Pharmacognosy, 36th ed. Nirali Prakashan, Pune.
Kroes BH, Van Den Berg AJ, Qarles Van Ufford HC, Van Dijk H and Labadie RP (1992). Anti-inflammatory activity of gallic acid. Planta Med 58(6): 499-504.
Kruidenier L and Verspaget HW (2002). Oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous. Aliment Pharmacol. Ther 16: 1997-2015.
Liliana, Hernandez, Javier, Palazon, Arturo and Navarro-Ocana (2013). The pentacyclic Triterpenoids alpha and beta amyrin. Planta Med : 401-405.
Mochizuki M and Hasegawa N (2005). Protective effect of Epigallcatechin Gallate on Acute Experimental Colitis. Journal of Health Science 51: 362-364.
Parkes M, and Jewell D. (2000). Ulcerative Colitis and Crohn’s disease: Molecular genetics and clinical implications. Expert Rev Mol Med. 2000: 1-18
Patel MA, Patel PK and Patel MB (2010). Effect of ethanol extract of Ficus begalensis on inflammatory bowel disease. Indian J Pharmacol 42: 214-218.
Prabhu VV and Guruvayoorappan C (2013). Protective effect of marine mangrove Rhizophora apiculata on acetic acid induced experimental colitis by regulating anti-oxidant enzymes, inflammatory mediators and nuclear factor-kappa B subunits. Int. Immunopharmacol 18: 1-11.
Prajapati, Purohit, Sharma and Kumar (2000). A Handbook of Medicinal Plants.
Razavi A, Khodadadi A, Eslami MB and Eshraghi S (2008). Therapeutic effect of sodium alginate in experimental chronic ulcerative colitis. Iran J Allergy Asthma Immunol 7: 13-18.
Ruzena Sotnikova, Viera Nosalova and Jana Navarova (2013). Efficacy of quercetin derivatives in prevention of ulcerative colitis in rats. Interdiscip Toxicol 6: 9-12.
Sang-Hyun Kim, Chang Duk Jun, Byung Ju Choi and Seunja Park (2005). Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. Toxicological Science 91(1): 123-131.
Sellin JH and Pasricha PJ (2009). Pharmacotherapy of inflammatory bowel disease- Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill Publications, NewYork.
Shifrin H, Milbauer MN , Shoham S and Weinstock M (2013). Rivastigmine Alleviates Experimentally Induced Colitis in Mice and Rats by Acting at Central and Peripheral Sites to Modulate Immune Responses. PLoS one 8: 1-11.
Smith NKB, Wallace JL, Morris GP and Whittle BJR (1988). The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat. Br. J. Pharmacol 94: 65-72.
Sourvah Bais (2013). Phytopharmacological Review on Leea indica. Inventi Journals(p)Limited. 14(1):
Ursino MG, Vasina V and Ponti FD (2009). Protection from DNBS-induced colitis by the tachykinin NK1 receptor antagonist SR140333 in rats. European Journal of Pharmacology 603: 133-137.
Vogel HG (2002). Drug Discovery and Evaluation Pharmacological Assays, 2nd ed; Springer-Verlag Berlin Heidelberg, New York.
Vrublova E (2010). The phytogenic feed additive Sangrovit modulates dextran sulfate sodium-induced colitis in rats. Veterinarni Medicina 55: 610–618.
Abreu M.T (2002). The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr. Gastroenterol 4: 481-489.
Adeleye GS, Nwozor CM and Okafor CB (2013). Effects of Dietary Advanced Lipid Oxidation End-products on Colitis Healing in Albino Rats. Journal of Environmental Issues and Agriculture in Developing Countries 5: 56-59.
Bickson SJ (1998). Treatment of chronic disease at the turn of the century. N Engl J Med 339: 401-2.
Button LA, Roberts SE, Goldacre MJ, Akbari A, Rodgers SE and Williams JG (2010). Hospitalized prevalence and 5-year mortality for IBD: Record linkage study. World. J Gastroenterol 16: 431-438.
Calkins BM and Mendeloff AI (1995). The epidemiology of idiopathic inflammatory bowel disease, 4th ed. Williams and wilkins, Baltimore.
Ellman GL (1959). Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 82: 70-76.
Frank I Tovey, Doga Capanoglu, G John Langley, Julie M Herniman, Serhat Bor and Michael Hobsely (2011). Dietary phytosterols protective against peptic ulceration. Gastroenterology Research 4(4):149-156.
Geetha T and Varalakshmi P (2001). Anti-inflammatory activity of lupeol in rats. Ethnopharmacol 76(1): 77-80.
Giriş M, Depboylu B, Doğru-Abbasoğlu S, Erbil Y, Olgaç V and Aliş H (2008). Effect of taurine on oxidative stress and apoptosis-related protein expression in trinitrobenzene sulphonic acid-induced colitis. Clin Exp Immunol 152: 102-110.
Gupta A, Bhatt MLB and Misra MK (2009). Lipid peroxidation and antioxidant status in head and neck squamous cell carcinoma patients. Oxidative Medicine and Cellular Longevity 2: 68-72.
Hagar HH, Medany AE, Eta EE and Arafa M (2007). Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid induced colitis in rats. European Journal of Pharmacology 554(1): 69-77.
Hana Strul MD and Nadir Arber MD (2000). Inflammatory bowel disease, ulcerative colitis, Crohn’s disease, pathophysiology, new therapies. IMAJ 2: 607-609.
Hofer N (2003). OraSl budesonide in management of Crohn's disease. Ann Pharmacother 37: 1457-1464.
Jagtap AG, Shrike SS and Phadke AS (2004). Effect of polyherbal formulation on experimental models of inflammatory bowel diseases. Journal of Ethnopharmacology 90: 195-204.
Kirtikar KR and Basu BD (2005). Indian Medicinal Plants, 2nd ed. Uttranchal (India).
Ko JKS, Lam FYL and Cheung APL (2005). Amelioration of experimental colitis by Astragalus membranaceus through anti-oxidation and inhibition of adhesion molecule synthesis. World J. Gastroenterol 11: 5787-5794.
Kokate CK, Purohit A and Gokhale S (1990). The Book of Pharmacognosy, 36th ed. Nirali Prakashan, Pune.
Kroes BH, Van Den Berg AJ, Qarles Van Ufford HC, Van Dijk H and Labadie RP (1992). Anti-inflammatory activity of gallic acid. Planta Med 58(6): 499-504.
Kruidenier L and Verspaget HW (2002). Oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous. Aliment Pharmacol. Ther 16: 1997-2015.
Liliana, Hernandez, Javier, Palazon, Arturo and Navarro-Ocana (2013). The pentacyclic Triterpenoids alpha and beta amyrin. Planta Med : 401-405.
Mochizuki M and Hasegawa N (2005). Protective effect of Epigallcatechin Gallate on Acute Experimental Colitis. Journal of Health Science 51: 362-364.
Parkes M, and Jewell D. (2000). Ulcerative Colitis and Crohn’s disease: Molecular genetics and clinical implications. Expert Rev Mol Med. 2000: 1-18
Patel MA, Patel PK and Patel MB (2010). Effect of ethanol extract of Ficus begalensis on inflammatory bowel disease. Indian J Pharmacol 42: 214-218.
Prabhu VV and Guruvayoorappan C (2013). Protective effect of marine mangrove Rhizophora apiculata on acetic acid induced experimental colitis by regulating anti-oxidant enzymes, inflammatory mediators and nuclear factor-kappa B subunits. Int. Immunopharmacol 18: 1-11.
Prajapati, Purohit, Sharma and Kumar (2000). A Handbook of Medicinal Plants.
Razavi A, Khodadadi A, Eslami MB and Eshraghi S (2008). Therapeutic effect of sodium alginate in experimental chronic ulcerative colitis. Iran J Allergy Asthma Immunol 7: 13-18.
Ruzena Sotnikova, Viera Nosalova and Jana Navarova (2013). Efficacy of quercetin derivatives in prevention of ulcerative colitis in rats. Interdiscip Toxicol 6: 9-12.
Sang-Hyun Kim, Chang Duk Jun, Byung Ju Choi and Seunja Park (2005). Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. Toxicological Science 91(1): 123-131.
Sellin JH and Pasricha PJ (2009). Pharmacotherapy of inflammatory bowel disease- Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill Publications, NewYork.
Shifrin H, Milbauer MN , Shoham S and Weinstock M (2013). Rivastigmine Alleviates Experimentally Induced Colitis in Mice and Rats by Acting at Central and Peripheral Sites to Modulate Immune Responses. PLoS one 8: 1-11.
Smith NKB, Wallace JL, Morris GP and Whittle BJR (1988). The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat. Br. J. Pharmacol 94: 65-72.
Sourvah Bais (2013). Phytopharmacological Review on Leea indica. Inventi Journals(p)Limited. 14(1):
Ursino MG, Vasina V and Ponti FD (2009). Protection from DNBS-induced colitis by the tachykinin NK1 receptor antagonist SR140333 in rats. European Journal of Pharmacology 603: 133-137.
Vogel HG (2002). Drug Discovery and Evaluation Pharmacological Assays, 2nd ed; Springer-Verlag Berlin Heidelberg, New York.
Vrublova E (2010). The phytogenic feed additive Sangrovit modulates dextran sulfate sodium-induced colitis in rats. Veterinarni Medicina 55: 610–618.
